Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC – Free Report) – Equities researchers at Roth Capital increased their Q3 2024 earnings estimates for shares of Cyclacel Pharmaceuticals in a research note issued on Wednesday, August 14th. Roth Capital analyst J. Aschoff now anticipates that the biotechnology company will earn ($0.54) per share for the quarter, up from their prior forecast of ($0.62). The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($4.93) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($2.29) EPS, FY2025 earnings at ($1.56) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at $4.26 EPS and FY2028 earnings at $6.67 EPS.
A number of other brokerages have also recently weighed in on CYCC. StockNews.com cut Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, June 27th. Roth Mkm decreased their price target on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, May 3rd.
Cyclacel Pharmaceuticals Stock Down 3.8 %
Cyclacel Pharmaceuticals stock opened at $1.27 on Monday. Cyclacel Pharmaceuticals has a twelve month low of $1.22 and a twelve month high of $11.34. The business has a fifty day moving average of $1.62 and a two-hundred day moving average of $2.04. The firm has a market cap of $1.85 million, a P/E ratio of -0.06 and a beta of 0.59.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,953.78% and a negative net margin of 21,963.75%. During the same quarter in the prior year, the business posted ($6.60) EPS.
Hedge Funds Weigh In On Cyclacel Pharmaceuticals
An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 23.58% of the stock is owned by hedge funds and other institutional investors.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Featured Articles
- Five stocks we like better than Cyclacel Pharmaceuticals
- Why Are These Companies Considered Blue Chips?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Business Services Stocks Investing
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.